DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Clinical trial NCT01619111 · COMPLETED

Trial details

NCT number: NCT01619111
Sponsor: Prof. Wolfgang Janni
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-negative Metastatic Breast Cancer HER2-positive Circulating Tumor Cells

Start date: 2012-02-01
Primary completion: 2022-01-01
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.